GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revelation Biosciences Inc (FRA:56U0) » Definitions » EV-to-EBITDA

Revelation Biosciences (FRA:56U0) EV-to-EBITDA : -1.07 (As of May. 14, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Revelation Biosciences EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Revelation Biosciences's enterprise value is €8.57 Mil. Revelation Biosciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was €-8.01 Mil. Therefore, Revelation Biosciences's EV-to-EBITDA for today is -1.07.

The historical rank and industry rank for Revelation Biosciences's EV-to-EBITDA or its related term are showing as below:

FRA:56U0' s EV-to-EBITDA Range Over the Past 10 Years
Min: -2.24   Med: 0   Max: 0
Current: -1.07

FRA:56U0's EV-to-EBITDA is ranked worse than
100% of 463 companies
in the Biotechnology industry
Industry Median: 9.32 vs FRA:56U0: -1.07

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-14), Revelation Biosciences's stock price is €8.88. Revelation Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €28.554. Therefore, Revelation Biosciences's PE Ratio for today is 0.31.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Revelation Biosciences EV-to-EBITDA Historical Data

The historical data trend for Revelation Biosciences's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revelation Biosciences EV-to-EBITDA Chart

Revelation Biosciences Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
- - 0.07 0.93

Revelation Biosciences Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.07 1.97 1.65 1.28 0.93

Competitive Comparison of Revelation Biosciences's EV-to-EBITDA

For the Biotechnology subindustry, Revelation Biosciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Revelation Biosciences's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Revelation Biosciences's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Revelation Biosciences's EV-to-EBITDA falls into.



Revelation Biosciences EV-to-EBITDA Calculation

Revelation Biosciences's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=8.569/-8.01
=-1.07

Revelation Biosciences's current Enterprise Value is €8.57 Mil.
Revelation Biosciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-8.01 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Revelation Biosciences  (FRA:56U0) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Revelation Biosciences's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=8.88/28.554
=0.31

Revelation Biosciences's share price for today is €8.88.
Revelation Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €28.554.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Revelation Biosciences EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Revelation Biosciences's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Revelation Biosciences (FRA:56U0) Business Description

Traded in Other Exchanges
Address
4660 La Jolla Village Drive, Suite 100, San Diego, CA, USA, 92122
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. It has several product candidates in development. REVTx-99, the lead therapeutic candidate, is an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2, including its variants, influenza A and B, parainfluenza, rhinovirus, and RSV. REVTx-99 is also being developed for other indications such as: allergic rhinitis and chronic nasal congestion. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx-200 is based on the same technology used in REVTx-99.

Revelation Biosciences (FRA:56U0) Headlines

No Headlines